Death · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Acute rejection · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in acute rejection compared with standard dose CNI (moderate certainty).
1 finding from 1 review
GFR · kidney transplant recipients
1 finding from 1 review
Graft loss · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: CMV infection · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: malignancy · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Relapse · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in relapse Time frame: 6 to 12 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Adverse effects: diabetes or hyperglycaemia · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: diabetes or hyperglycaemia compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse effects: obesity or Cushing's Syndrome · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: obesity or Cushing's Syndrome compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: hypertension · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: hypertension compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse effects: acne · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids may leads to lower adverse effects: acne compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute rejection: avoidance · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in acute rejection: avoidance compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Acute rejection: late withdrawal · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).
1 finding from 1 review
GFR: avoidance · kidney transplant recipients
1 finding from 1 review
GFR: late withdrawal · kidney transplant recipients
1 finding from 1 review
Graft loss: avoidance · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: avoidance compared with standard dose CNI (moderate certainty).
1 finding from 1 review